As a result, topical AR antagonists are considereda more appropriate therapeutic approach for AGA, but no such compoundshave yet received clinical approval for this indication. Clascoterone, a topical soft drug approved in2020 for acne, is a competitive AR antagonistcurrently being evaluated in phase III (NCT05910450 and NCT05914805)trials for AGA. The gene discussed is AR; the disease is acne.